Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients. MELSUNGEN, Germany and MONMOUTH JUNCTION, N.J., March 2, 2021 /PRNewswire/ — B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation […]
ctso-20201231x10k001.jpg
Hip Replacement Devices Market Size, Share, Trends, Scope & Forecast
Dental disaster: One year after first lockdowns dentists around
B. Braun and CytoSorbents Announce Global Co-Marketing Agreement
A Month's-End Associated Press (AP) Photographic Celebration Of
Organization, Facts & Figures
A Month's-End Associated Press (AP) Photographic Celebration Of
Mouro Capital (Santander) impulsa una 'joint venture' de Clikalia
Facts & Figures - B. Braun
Velocity Global's 2022 Work In Progress Report: Businesses and
Nouvelles officielles de Cooperation 2024
Leap by McKinsey Research Shows 50 Percent of Global Revenue Will
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement
Organization
In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum
__44636.1544738318.jpg)
